CN103781476B - 包含芳香酶抑制剂的药物组合物 - Google Patents

包含芳香酶抑制剂的药物组合物 Download PDF

Info

Publication number
CN103781476B
CN103781476B CN201280043614.7A CN201280043614A CN103781476B CN 103781476 B CN103781476 B CN 103781476B CN 201280043614 A CN201280043614 A CN 201280043614A CN 103781476 B CN103781476 B CN 103781476B
Authority
CN
China
Prior art keywords
pharmaceutical composition
mixture
capsule
weight
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280043614.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103781476A (zh
Inventor
A·泰勒
L·B·克里克斯坦
J·塔库尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46846026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103781476(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN103781476A publication Critical patent/CN103781476A/zh
Application granted granted Critical
Publication of CN103781476B publication Critical patent/CN103781476B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280043614.7A 2011-09-08 2012-09-06 包含芳香酶抑制剂的药物组合物 Active CN103781476B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161532459P 2011-09-08 2011-09-08
US61/532,459 2011-09-08
US201261638588P 2012-04-26 2012-04-26
US61/638,588 2012-04-26
PCT/US2012/053846 WO2013036563A1 (en) 2011-09-08 2012-09-06 Pharmaceutical compositions comprising an aromatase inhibitor

Publications (2)

Publication Number Publication Date
CN103781476A CN103781476A (zh) 2014-05-07
CN103781476B true CN103781476B (zh) 2016-12-07

Family

ID=46846026

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280043614.7A Active CN103781476B (zh) 2011-09-08 2012-09-06 包含芳香酶抑制剂的药物组合物
CN201280043378.9A Active CN103796644B (zh) 2011-09-08 2012-09-06 芳香酶抑制剂用于治疗性腺功能减退和相关疾病的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280043378.9A Active CN103796644B (zh) 2011-09-08 2012-09-06 芳香酶抑制剂用于治疗性腺功能减退和相关疾病的用途

Country Status (31)

Country Link
US (4) US9370505B2 (en:Method)
EP (2) EP2753313B1 (en:Method)
JP (2) JP6051467B2 (en:Method)
KR (3) KR20140071358A (en:Method)
CN (2) CN103781476B (en:Method)
AR (1) AR087790A1 (en:Method)
AU (2) AU2012304693B2 (en:Method)
BR (2) BR112014005434B1 (en:Method)
CA (2) CA2845929C (en:Method)
CL (1) CL2014000552A1 (en:Method)
CY (2) CY1118461T1 (en:Method)
DK (2) DK2753313T3 (en:Method)
ES (2) ES2613666T3 (en:Method)
HR (2) HRP20170002T1 (en:Method)
HU (2) HUE031435T2 (en:Method)
IL (1) IL231234A (en:Method)
IN (1) IN2014DN01619A (en:Method)
LT (2) LT2753313T (en:Method)
MX (2) MX343902B (en:Method)
PE (1) PE20141584A1 (en:Method)
PH (1) PH12014500435A1 (en:Method)
PL (2) PL2753312T3 (en:Method)
PT (2) PT2753313T (en:Method)
RU (2) RU2617510C2 (en:Method)
SG (2) SG10201607503WA (en:Method)
SI (2) SI2753312T1 (en:Method)
TN (1) TN2014000059A1 (en:Method)
TW (1) TW201316987A (en:Method)
UY (1) UY34315A (en:Method)
WO (2) WO2013036563A1 (en:Method)
ZA (1) ZA201401040B (en:Method)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN01619A (en:Method) * 2011-09-08 2015-05-15 Novartis Ag
US10324099B2 (en) * 2014-03-26 2019-06-18 The Regents Of The University Of California Ultrasensitive androgen receptor bioassay
JP6731136B2 (ja) * 2014-07-07 2020-07-29 レコルダティ アーゲー 医薬製剤
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN110520110A (zh) * 2017-03-08 2019-11-29 阿瑞雅德制药公司 包含5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的药物制剂
USD894149S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
USD894148S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
JP7121999B2 (ja) * 2019-09-26 2022-08-19 学校法人九州文化学園 男性性腺機能低下症治療剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227393A (en) * 1990-12-12 1993-07-13 Ciba-Geigy Corporation α-fluoro-α-tetrazolyl-phenylmethyl derivatives useful as aromatase inhibitors
WO2003082254A1 (en) * 2002-04-03 2003-10-09 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
AU2001271162A1 (en) * 2000-07-05 2002-01-14 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
WO2002083240A1 (en) * 2001-04-17 2002-10-24 Ares Trading S.A. Aromatase inhibition to enhance assisted reproduction
US7101573B2 (en) 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
WO2006114702A2 (en) 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CN102335219A (zh) 2007-11-21 2012-02-01 客乐谐制药株式会社 芳香酶抑制剂
IN2014DN01619A (en:Method) * 2011-09-08 2015-05-15 Novartis Ag

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227393A (en) * 1990-12-12 1993-07-13 Ciba-Geigy Corporation α-fluoro-α-tetrazolyl-phenylmethyl derivatives useful as aromatase inhibitors
WO2003082254A1 (en) * 2002-04-03 2003-10-09 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male

Also Published As

Publication number Publication date
UY34315A (es) 2013-04-30
KR20140071358A (ko) 2014-06-11
JP6051467B2 (ja) 2016-12-27
HUE031435T2 (en) 2017-07-28
BR112014004879B1 (pt) 2020-01-28
HRP20170003T1 (hr) 2017-03-10
ES2613667T3 (es) 2017-05-25
LT2753312T (lt) 2017-01-25
DK2753313T3 (en) 2017-02-13
CN103796644A (zh) 2014-05-14
PT2753313T (pt) 2017-02-02
BR112014005434A2 (pt) 2017-04-04
JP2014528932A (ja) 2014-10-30
DK2753312T3 (da) 2017-02-13
RU2014113575A (ru) 2015-10-20
JP6280501B2 (ja) 2018-02-14
KR101872561B1 (ko) 2018-06-28
AU2012304694B2 (en) 2016-04-07
TN2014000059A1 (en) 2015-07-01
CL2014000552A1 (es) 2014-09-12
IL231234A (en) 2016-12-29
EP2753313B1 (en) 2016-12-14
SI2753312T1 (sl) 2017-10-30
US9750724B2 (en) 2017-09-05
EP2753313A1 (en) 2014-07-16
US20140213622A1 (en) 2014-07-31
MX2014002773A (es) 2014-06-05
US20160346257A1 (en) 2016-12-01
CN103781476A (zh) 2014-05-07
SI2753313T1 (sl) 2017-04-26
IL231234A0 (en) 2014-04-30
TW201316987A (zh) 2013-05-01
WO2013036563A1 (en) 2013-03-14
CA2845929A1 (en) 2013-03-14
CA2845929C (en) 2018-06-19
PH12014500435A1 (en) 2019-03-22
MX360315B (es) 2018-10-29
NZ621476A (en) 2016-02-26
RU2617510C2 (ru) 2017-04-25
US9295668B2 (en) 2016-03-29
LT2753313T (lt) 2017-02-10
PL2753312T3 (pl) 2017-06-30
RU2628808C2 (ru) 2017-08-22
ZA201401040B (en) 2015-12-23
BR112014005434B1 (pt) 2021-01-05
US10064844B2 (en) 2018-09-04
PL2753313T3 (pl) 2017-07-31
US20160243084A1 (en) 2016-08-25
CA2846884C (en) 2019-04-09
BR112014004879A2 (pt) 2017-03-14
IN2014DN01619A (en:Method) 2015-05-15
KR20140058619A (ko) 2014-05-14
CA2846884A1 (en) 2013-03-14
HUE031478T2 (hu) 2017-07-28
AU2012304693A1 (en) 2014-03-13
CY1118499T1 (el) 2017-07-12
CN103796644B (zh) 2017-05-03
ES2613666T3 (es) 2017-05-25
KR20180030254A (ko) 2018-03-21
US20140309267A1 (en) 2014-10-16
AR087790A1 (es) 2014-04-16
US9370505B2 (en) 2016-06-21
PT2753312T (pt) 2017-02-03
MX343902B (es) 2016-11-28
RU2014113334A (ru) 2015-10-20
HRP20170002T1 (hr) 2017-02-24
MX2014002780A (es) 2014-06-05
AU2012304693B2 (en) 2016-03-31
SG10201607503WA (en) 2016-10-28
WO2013036562A1 (en) 2013-03-14
CY1118461T1 (el) 2017-07-12
SG2014012132A (en) 2014-06-27
PE20141584A1 (es) 2014-11-13
EP2753312A1 (en) 2014-07-16
AU2012304694A1 (en) 2014-03-20
EP2753312B1 (en) 2016-12-14
JP2014526465A (ja) 2014-10-06

Similar Documents

Publication Publication Date Title
CN103781476B (zh) 包含芳香酶抑制剂的药物组合物
US10561615B2 (en) Testosterone undecanoate compositions
US9375437B2 (en) Progesterone containing oral dosage forms and kits
CN105979935B (zh) 包含雌四醇组分的口崩固体剂量单位
MXPA04006057A (es) Productos farmaceuticos orales que contienen 3-alcanoato inferior de 17-beta-estradiol, metodo para administrar los mismos y proceso de preparacion.
TW200526206A (en) Treatment of aromatase inhibitor therapy-related osteoporosis
KR102612983B1 (ko) 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법
CN107206011B (zh) 包括雷洛昔芬以及维生素d或其衍生物的复合胶囊
EA013262B1 (ru) Пероральные твёрдые лекарственные формы, содержащие низкую дозу эстрадиола
CN101623287B (zh) 一种屈螺酮类似物的治疗更年期综合症的药物组合物
US20190192485A1 (en) Dosage regimen for the treatment of endometriosis
CN101623290A (zh) 一种屈螺酮类似物药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant